|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0008625,
umls-concept:C0008626,
umls-concept:C0023473,
umls-concept:C0030705,
umls-concept:C0031525,
umls-concept:C0087111,
umls-concept:C0162340,
umls-concept:C0172367,
umls-concept:C0175668,
umls-concept:C0282411,
umls-concept:C0439849,
umls-concept:C0441712,
umls-concept:C0445223,
umls-concept:C0683598,
umls-concept:C0939537,
umls-concept:C1280500,
umls-concept:C1552599,
umls-concept:C1704787,
umls-concept:C1853126
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2003-4-9
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1248-52
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12684391-Antineoplastic Agents,
pubmed-meshheading:12684391-Drug Resistance, Neoplasm,
pubmed-meshheading:12684391-Fusion Proteins, bcr-abl,
pubmed-meshheading:12684391-Humans,
pubmed-meshheading:12684391-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:12684391-Piperazines,
pubmed-meshheading:12684391-Pyrimidines
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.
|
|
pubmed:affiliation |
Division of Hematology and Oncology, Department of Internal Medicine, The James Cancer Hospital and The Comprehensive Cancer Center at The Ohio State University, Columbus, Ohio 43210, USA. marcucci-1@medctr.osu.edu
|
|
pubmed:publicationType |
Journal Article,
Comment,
Research Support, U.S. Gov't, P.H.S.,
Review,
Research Support, Non-U.S. Gov't
|
